Total
0
Shares
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald
CEO, Marc Voigt
Source: Finance News Network
  • Biotech company Immutep (IMM) has received €2,173,454 (roughly A$3.6 million) from the French Government
  • The funds come from a research and development (R&D) tax incentive payment
  • The French Research Tax Credit gives a 30 per cent reimbursement to French companies for research and development activities in Europe
  • Immutep qualifies to receive the tax incentive through its subsidiary, which has a laboratory in southwest Paris
  • Funds from the incentive will be used to support Immutep's metastatic breast cancer treatment and the development of its IMP761 drug for autoimmune diseases
  • Immutep is up 1.08 per cent on the market this morning, selling shares for 19 cents each

Biotech company, Immutep (IMM) has received $3.6 million (€2,173,454) from the French Government.

The funds come from a research and development (R&D) tax incentive payment, under Immutep's Crédit d’Impôt Recherche (CIR) scheme.

Crédit d’Impôt Recherche means Research Tax Credit and is a French Government tax incentive, which gives a 30 per cent reimbursement to French companies for research and development activities in Europe.

Immutep qualifies to receive the tax incentive through its subsidiary, Immutep S.A.S., as it has a laboratory at Châtenay-Malabry in southwest Paris.

Funds from the incentive will be used to support Immutep's metastatic breast cancer treatment and the development of its IMP761 drug for autoimmune diseases.

The former treatment, efti, is an anti-cancer drug that is designed to treat the most advanced stage of breast cancer. Earlier this month, efti was granted a patent from the Japanese Patent Office.

Immutep is up 1.08 per cent on the market this morning, selling shares for 19 cents each at 11:06 am AEST.


Subscribe


IMM by the numbers
More From The Market Herald
OBJ (ASX:OBJ) - CEO, Paul Peros - The Market Herald

" OBJ (ASX:OBJ) to raise $4.5M for product development and licencing

Innovative wellness company OBJ (OBJ) is aiming to raise $4.5 million through an entitlement offer and placement for licencing, development and general workin…
Creso Pharma (ASX:CPH) - CEO & Co Founder, Dr Miri Halperin Wernli (left) and Chairman, Boaz Wachtel (right) - The Market Herald

" Creso Pharma (ASX:CPH) subsidiary receives follow-up order from Univo Pharmaceuticals

Creso Pharma’s (CPH) subsidiary, Mernova Medicinal, has received a US$625,690 (roughly A$901,830) purchase order from Univo Pharmaceuticals.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech (ASX:HCT) misses the mark for hand sanitiser product

Holista CollTech (HCT) has downgraded its $3.8 million in expected sales from its hand sanitiser product, Natshield, due to COVID-19 and race riots.
Cellmid (ASX:CDY) - CEO, Maria Halasz (right) - The Market Herald

" Cellmid (ASX:CDY) signs distribution agreement for SARS-CoV-2 and ELISA’s

Cellmid (CDY) has signed a distribution agreement with Immunodiagnostics (IMD) for Enzyme Linked Immunosorbent Assays (ELISA’s) and SARS-CoV-2 tests in Australia and New